Literature DB >> 20087935

Impact of changes in antigen level on CD38/PD-1 co-expression on HIV-specific CD8 T cells in chronic, untreated HIV-1 infection.

Thomas Vollbrecht1, Heike Brackmann, Nadja Henrich, Joerg Roeling, Ulrich Seybold, Johannes R Bogner, Frank D Goebel, Rika Draenert.   

Abstract

Excessive immune activation is a hallmark of chronic uncontrolled HIV infection. During the past years, growing evidence suggests that immune inhibitory signals also play an important role in progressive disease. However, the relationship between positive and negative immune signals on HIV-specific CD8 T cells has not been studied in detail so far in chronic HIV-1 infection. In this study, the expression of markers of positive (CD38) and negative (PD-1) immune signals on virus-specific CD8 T cells in chronic, untreated HIV-1 infection was evaluated using intracellular cytokine staining. Viral escape mutations were assessed by autologous virus sequence analysis and subsequent peptide titration assays. Single-epitope CD8 T-cell responses toward Gag, Pol, and Nef were compared in 12 HIV-1 controllers (viral load <5,000 cp/ml) and 12 HIV-1 progressors (viral load >50,000 cp/ml) and a highly significant increase of CD38/PD-1 co-expression on virus-specific CD8 T cells in progressors was found (P < 0.0001). The level of CD38/PD-1 co-expression was independent of epitope specificity. Longitudinal follow-up revealed a clear drop in CD38/PD-1 co-expression on virus-specific CD8 T cells after the suppression of antigen following either viral escape mutation or the initiation of HAART (P = 0.004). Antigen persistence with a fluctuating viral load revealed stable levels of CD38/PD-1 co-expression whereas significant rises in viral load were accompanied or even preceded by substantial increases in CD38/PD-1 co-expression. The CD38/PD-1 phenotype clearly distinguishes HIV-specific CD8 T-cell responses between controllers and progressors. Whether it plays a causative role in disease progression remains debatable. J. Med. Virol. 82:358-370, 2010. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087935     DOI: 10.1002/jmv.21723

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  22 in total

1.  Antiretroviral therapy reduces the magnitude and T cell receptor repertoire diversity of HIV-specific T cell responses without changing T cell clonotype dominance.

Authors:  Joseph A Conrad; Ramesh K Ramalingam; Coley B Duncan; Rita M Smith; Jie Wei; Louise Barnett; Brenna C Simons; Shelly L Lorey; Spyros A Kalams
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

2.  Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses.

Authors:  Zaza M Ndhlovu; Jacqueline Proudfoot; Kevin Cesa; Donna Marie Alvino; Ashley McMullen; Seanna Vine; Eleni Stampouloglou; Alicja Piechocka-Trocha; Bruce D Walker; Florencia Pereyra
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

Review 3.  Signaling through the P38 and ERK pathways: a common link between HIV replication and the immune response.

Authors:  Robert L Furler; Christel H Uittenbogaart
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

Review 4.  Revisiting immune exhaustion during HIV infection.

Authors:  Alka Khaitan; Derya Unutmaz
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

5.  Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers.

Authors:  Julia M Shaw; Peter W Hunt; J William Critchfield; Delandy H McConnell; Juan Carlos Garcia; Richard B Pollard; Ma Somsouk; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

6.  Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory.

Authors:  Thorsten Demberg; Amelia C Ettinger; Stanley Aladi; Katherine McKinnon; Thea Kuddo; David Venzon; L Jean Patterson; Terry M Phillips; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2011-06-25       Impact factor: 3.641

7.  Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation.

Authors:  Julia M Shaw; Peter W Hunt; J William Critchfield; Delandy H McConnell; Juan Carlos Garcia; Richard B Pollard; Ma Somsouk; Steven G Deeks; Barbara L Shacklett
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-16       Impact factor: 2.205

8.  Antiretroviral therapy down-regulates innate antiviral response genes in patients with AIDS in sub-saharan Africa.

Authors:  David R Boulware; David B Meya; Tracy L Bergemann; Darlisha Williams; Irina A Vlasova-St Louis; Josh Rhein; Jack Staddon; Andrew Kambugu; Edward N Janoff; Paul R Bohjanen
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

9.  Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage.

Authors:  Thomas C Greenough; Shalyn C Campellone; Robin Brody; Surbhi Jain; Victor Sanchez-Merino; Mohan Somasundaran; Katherine Luzuriaga
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

10.  Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation.

Authors:  Loury Janbazian; David A Price; Glenda Canderan; Abdelali Filali-Mouhim; Tedi E Asher; David R Ambrozak; Phillip Scheinberg; Mohamad Rachid Boulassel; Jean-Pierre Routy; Richard A Koup; Daniel C Douek; Rafick-Pierre Sekaly; Lydie Trautmann
Journal:  J Immunol       Date:  2011-12-30       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.